Journal of Shanghai Jiao Tong University (Medical Science) >

2025 , Vol. 45 >Issue 5: 646 - 652

DOI: https://doi.org/10.3969/j.issn.1674-8115.2025.05.014

Review

Current research status of imaging markers for cognitive impairment in Parkinson′s disease

  • CAO Mingming ,
  • WANG Hui ,
  • YIN Yafu
Expand
  • Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
YIN Yafu, E-mail: yinyf-2001@163.com.

Received date: 2025-01-03

  Accepted date: 2025-02-26

  Online published: 2025-05-19

Fold

Abstract

Parkinson′s disease (PD), the second most prevalent neurodegenerative disease, has shown an increasing incidence in recent years, significantly impacting the quality of life of elderly individuals and their families. The onset of cognitive impairment and Parkinson′s disease dementia (PDD) are critical milestones in the progression of PD. Imaging examinations, serving as essential detection and evaluation tools for neurodegenerative diseases, have been increasingly applied to PD-related research. Different imaging techniques demonstrate distinct advantages and features in screening cognitive dysfunction in PD. Choosing a reliable imaging method not only maximizes the advantages of the examination, enhancing the sensitivity and specificity in identifying PD patients at risk of cognitive impairment, but also reduces the frequency of examinations and the radiation dose received by patients. This review summarizes the existing findings on imaging markers of cognitive impairment in PD from three aspects, structural imaging, functional imaging, and multimodal techniques. Furthermore, it explores future research directions, aiming to provide powerful imaging support for the clinical diagnosis and treatment of PD.

Key words： Parkinson′s disease; cognitive impairment; imaging marker; structural imaging; functional imaging; multimodal technique

Cite this article

CAO Mingming , WANG Hui , YIN Yafu . Current research status of imaging markers for cognitive impairment in Parkinson′s disease[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(5) : 646 -652 . DOI: 10.3969/j.issn.1674-8115.2025.05.014

References

1 WEINTRAUB D, CASPELL-GARCIA C, SIMUNI T, et al. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease[J]. Ann Clin Transl Neurol, 2020, 7(4): 449-461.
2 PIGOTT J S, DAVIES N, CHESTERMAN E, et al. Delivering optimal care to people with cognitive impairment in Parkinson′s disease: a qualitative study of patient, caregiver, and professional perspectives[J]. Parkinsons Dis, 2023, 2023: 9732217.
3 NIU J Q, ZHONG Y, JIN C T, et al. Positron emission tomography imaging of synaptic dysfunction in Parkinson′s disease[J]. Neurosci Bull, 2024, 40(6): 743-758.
4 JOHAR I, MOLLENHAUER B, AARSLAND D. Cerebrospinal fluid biomarkers of cognitive decline in Parkinson′s disease[J]. Int Rev Neurobiol, 2017, 132: 275-294.
5 FILIPPI M, CANU E, DONZUSO G, et al. Tracking cortical changes throughout cognitive decline in Parkinson′s disease[J]. Mov Disord, 2020, 35(11): 1987-1998.
6 SARASSO E, AGOSTA F, PIRAMIDE N, et al. Progression of grey and white matter brain damage in Parkinson′s disease: a critical review of structural MRI literature[J]. J Neurol, 2021, 268(9): 3144-3179.
7 GAO Y Y, NIE K, HUANG B, et al. Changes of brain structure in Parkinson′s disease patients with mild cognitive impairment analyzed via VBM technology[J]. Neurosci Lett, 2017, 658: 121-132.
8 JIANG Y Q, CHEN Q Z, YANG Y, et al. White matter lesions contribute to motor and non-motor disorders in Parkinson′s disease: a critical review[J]. Geroscience, 2025, 47(1): 591-609.
9 DADAR M, GEE M, SHUAIB A, et al. Cognitive and motor correlates of grey and white matter pathology in Parkinson′s disease[J]. Neuroimage Clin, 2020, 27: 102353.
10 SCAMARCIA P G, AGOSTA F, SPINELLI E G, et al. Longitudinal white matter damage evolution in Parkinson′s disease[J]. Mov Disord, 2022, 37(2): 315-324.
11 JEONG S H, LEE H S, JUNG J H, et al. Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-na?ve Parkinson′s disease[J]. Parkinsonism Relat Disord, 2022, 97: 1-7.
12 HANNING U, TEUBER A, LANG E, et al. White matter hyperintensities are not associated with cognitive decline in early Parkinson′s disease: the DeNoPa cohort[J]. Parkinsonism Relat Disord, 2019, 69: 61-67.
13 DE BARTOLO M I, OJHA A, LEODORI G, et al. Association of early fMRI connectivity alterations with different cognitive phenotypes in patients with newly diagnosed parkinson disease[J]. Neurology, 2025, 104(1): e210192.
14 ZARIFKAR P, KIM J, LA C, et al. Cognitive impairment in Parkinson′s disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ[J]. Parkinsonism Relat Disord, 2021, 83: 71-78.
15 WANG Z J, JIA X Q, CHEN H M, et al. Abnormal spontaneous brain activity in early Parkinson′s disease with mild cognitive impairment: a resting-state fMRI study[J]. Front Physiol, 2018, 9: 1093.
16 CAMPBELL M C, JACKSON J J, KOLLER J M, et al. Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease[J]. Neurology, 2020, 94(7): e718-e728.
17 XING Y L, FU S S, LI M, et al. Regional neural activity changes in Parkinson′s disease-associated mild cognitive impairment and cognitively normal patients[J]. Neuropsychiatr Dis Treat, 2021, 17: 2697-2706.
18 WANG Q G, HE W, LIU D H, et al. Functional connectivity in Parkinson′s disease patients with mild cognitive impairment[J]. Int J Gen Med, 2021, 14: 2623-2630.
19 CHEN L, HUANG T, MA D, et al. Altered default mode network functional connectivity in Parkinson′s disease: a resting-state functional magnetic resonance imaging study[J]. Front Neurosci, 2022, 16: 905121.
20 IMARISIO A, PILOTTO A, PREMI E, et al. Atypical brain FDG-PET patterns increase the risk of long-term cognitive and motor progression in Parkinson′s disease[J]. Parkinsonism Relat Disord, 2023, 115: 105848.
21 HOLMES S, TINAZ S. Neuroimaging biomarkers in Parkinson′s disease[J]. Adv Neurobiol, 2024, 40: 617-663.
22 BOOTH S, KO J H. Radionuclide imaging of the neuroanatomical and neurochemical substrate of cognitive decline in Parkinson′s disease[J]. Nucl Med Mol Imaging, 2024, 58(4): 213-226.
23 MEYER P T, FRINGS L, RüCKER G, et al. 18F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment[J]. J Nucl Med, 2017, 58(12): 1888-1898.
24 BABA T, HOSOKAI Y, NISHIO Y, et al. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson′s disease[J]. J Neurol Sci, 2017, 372: 288-293.
25 YOO H S, KIM H K, NA H K, et al. Association of striatal dopamine depletion and brain metabolism changes with motor and cognitive deficits in patients with parkinson disease[J]. Neurology, 2024, 103(12): e210105.
26 BIDESI N S R, VANG ANDERSEN I, WINDHORST A D, et al. The role of neuroimaging in Parkinson′s disease[J]. J Neurochem, 2021, 159(4): 660-689.
27 CHUNG S J, YOO H S, OH J S, et al. Effect of striatal dopamine depletion on cognition in de novo Parkinson′s disease[J]. Parkinsonism Relat Disord, 2018, 51: 43-48.
28 CHRISTOPHER L, MARRAS C, DUFF-CANNING S, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson′s disease with mild cognitive impairment[J]. Brain, 2014, 137(Pt 2): 565-575.
29 SASIKUMAR S, STRAFELLA A P. Imaging mild cognitive impairment and dementia in Parkinson′s disease[J]. Front Neurol, 2020, 11: 47.
30 HONG Y J, CHOI S H, KIM S, et al. Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: results of the CoSCo study[J]. Alzheimers Dement, 2025, 21(2): e14473.
31 CHUN M Y, CHUNG S J, KIM S H, et al. Hippocampal perfusion affects motor and cognitive functions in parkinson disease: an early phase 18F-FP-CIT positron emission tomography study[J]. Ann Neurol, 2024, 95(2): 388-399.
32 WITZIG V, PJONTEK R, TAN S H, et al. Modulating the cholinergic system: novel targets for deep brain stimulation in Parkinson′s disease[J]. J Neurochem, 2025, 169(2): e16264.
33 KALBE E, FOLKERTS A K, WITT K, et al. German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson′s disease: new spotlights on diagnostic procedures and non-pharmacological interventions[J]. J Neurol, 2024, 271(11): 7330-7357.
34 SLATER N M, MELZER T R, MYALL D J, et al. Cholinergic basal forebrain integrity and cognition in Parkinson′s disease: a reappraisal of magnetic resonance imaging evidence[J]. Mov Disord, 2024, 39(12): 2155-2172.
35 VAN DER ZEE S, MüLLER M L T M, KANEL P, et al. Cholinergic denervation patterns across cognitive domains in Parkinson′s disease[J]. Mov Disord, 2021, 36(3): 642-650.
36 SCHUMACHER J, RAY N, TEIPEL S, et al. Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers[J]. NPJ Parkinsons Dis, 2024, 10(1): 127.
37 BOHNEN N I, ALBIN R L, MüLLER M L T M, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects[J]. JAMA Neurol, 2015, 72(2): 194-200.
38 SOARES é N, COSTA A C D S, FERROLHO G J, et al. Nicotinic acetylcholine receptors in glial cells as molecular target for Parkinson′s disease[J]. Cells, 2024, 13(6): 474.
39 GOMPERTS S N, LOCASCIO J J, MAKARETZ S J, et al. Tau positron emission tomographic imaging in the Lewy body diseases[J]. JAMA Neurol, 2016, 73(11): 1334-1341.
40 ZHANG J J, JIN J N, SU D N, et al. Tau-PET imaging in Parkinson′s disease: a systematic review and meta-analysis[J]. Front Neurol, 2023, 14: 1145939.
41 MIHAESCU A S, VALLI M, URIBE C, et al. Beta amyloid deposition and cognitive decline in Parkinson′s disease: a study of the PPMI cohort[J]. Mol Brain, 2022, 15(1): 79.
42 WINER J R, MAASS A, PRESSMAN P, et al. Associations between tau, β-amyloid, and cognition in parkinson disease[J]. JAMA Neurol, 2018, 75(2): 227-235.
43 PAJARES M, ROJO A I, MANDA G, et al. Inflammation in Parkinson′s disease: mechanisms and therapeutic implications[J]. Cells, 2020, 9(7): 1687.
44 ISIK S, YEMAN KIYAK B, AKBAYIR R, et al. Microglia mediated neuroinflammation in Parkinson′s disease[J]. Cells, 2023, 12(7): 1012.
45 THEIS H, PAVESE N, REKTOROVá I, et al. Imaging biomarkers in prodromal and earliest phases of Parkinson′s disease[J]. J Parkinsons Dis, 2024, 14(s2): S353-S365.
46 ZHANG P F, GAO F. Neuroinflammation in Parkinson′s disease: a meta-analysis of PET imaging studies[J]. J Neurol, 2022, 269(5): 2304-2314.
47 EDISON P, AHMED I, FAN Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson′s disease with and without dementia[J]. Neuropsychopharmacology, 2013, 38(6): 938-949.
48 KOULI A, SPINDLER L R B, FRYER T D, et al. Neuroinflammation is linked to dementia risk in Parkinson′s disease[J]. Brain, 2024, 147(3): 923-935.
49 PERERA MOLLIGODA ARACHCHIGE A S, GARNER A K. Seven tesla MRI in Alzheimer′s disease research: state of the art and future directions: a narrative review[J]. AIMS Neurosci, 2023, 10(4): 401-422.
50 KHAN M A, HAIDER N, SINGH T, et al. Promising biomarkers and therapeutic targets for the management of Parkinson′s disease: recent advancements and contemporary research[J]. Metab Brain Dis, 2023, 38(3): 873-919.
51 WIELER M, GEE M, WAYNE MARTIN W R. Longitudinal midbrain changes in early Parkinson′s disease: iron content estimated from R2*/MRI[J]. Parkinsonism Relat Disord, 2015, 21(3): 179-183.
52 WELTON T, HARTONO S, SHIH Y C, et al. Ultra-high-field 7T MRI in Parkinson′s disease: ready for clinical use? A narrative review[J]. Quant Imaging Med Surg, 2023, 13(11): 7607-7620.
53 GRIMALDI S, EL MENDILI M M, ZAARAOUI W, et al. Increased sodium concentration in substantia nigra in early Parkinson′s disease: a preliminary study with ultra-high field (7T) MRI[J]. Front Neurol, 2021, 12: 715618.
54 XIAO K M, LI J L, ZHOU L Y, et al. Retinopathy in Parkinson′s disease: a potential biomarker for early diagnosis and clinical assessment[J]. Neuroscience, 2025, 565: 202-210.
55 HANNAWAY N, ZARKALI A, LEYLAND L A, et al. Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson′s disease[J]. J Neurol Neurosurg Psychiatry, 2023, 94(9): 742-750.
56 CHRYSOU A, HEIKKA T, VAN DER ZEE S, et al. Reduced thickness of the retina in de novo Parkinson′s disease shows a distinct pattern, different from glaucoma[J]. J Parkinsons Dis, 2024, 14(3): 507-519.
57 ZHANG J R, CAO Y L, LI K, et al. Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson′s disease: a longitudinal study[J]. Parkinsonism Relat Disord, 2021, 82: 92-97.
58 MURUETA-GOYENA A, ROMERO-BASCONES D, TEIJEIRA-PORTAS S, et al. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson′s disease[J]. NPJ Parkinsons Dis, 2024, 10(1): 26.
59 SHI M G, FENG X M, ZHI H Y, et al. Machine learning-based radiomics in neurodegenerative and cerebrovascular disease[J]. MedComm, 2024, 5(11): e778.
60 BU S T, PANG H Z, LI X L, et al. Multi-parametric radiomics of conventional T1 weighted and susceptibility-weighted imaging for differential diagnosis of idiopathic Parkinson′s disease and multiple system atrophy[J]. BMC Med Imaging, 2023, 23(1): 204.
61 PANAHI M, HOSSEINI M S. Multi-modality radiomics of conventional T1 weighted and diffusion tensor imaging for differentiating Parkinson′s disease motor subtypes in early-stages[J]. Sci Rep, 2024, 14(1): 20708.
62 OLIVEIRA G C, PAH N D, NGO Q C, et al. A pilot study for speech assessment to detect the severity of Parkinson′s disease: an ensemble approach[J]. Comput Biol Med, 2025, 185: 109565.
63 ZHU Y Y, WANG F, NING P P, et al. Multimodal neuroimaging-based prediction of Parkinson′s disease with mild cognitive impairment using machine learning technique[J]. NPJ Parkinsons Dis, 2024, 10(1): 218.
Options
Outlines

/

〈 〉